U.S. Markets closed

Medpace Holdings, Inc. (MEDP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
177.54-4.25 (-2.34%)
At close: 4:00PM EDT
178.56 +1.02 (0.57%)
After hours: 04:41PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close181.79
Open179.57
Bid148.00 x 900
Ask250.00 x 1100
Day's Range175.13 - 182.02
52 Week Range85.22 - 196.12
Volume373,879
Avg. Volume187,226
Market Cap6.387B
Beta (5Y Monthly)1.36
PE Ratio (TTM)42.04
EPS (TTM)4.22
Earnings DateJul 26, 2021 - Jul 30, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est180.25
  • Medpace Holdings, Inc. to Report Second Quarter 2021 Financial Results on July 26, 2021
    Business Wire

    Medpace Holdings, Inc. to Report Second Quarter 2021 Financial Results on July 26, 2021

    Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced that it will report its second quarter 2021 financial results after the market close on Monday, July 26, 2021. The Company will host a conference call the following morning, Tuesday, July 27, 2021, at 9:00 a.m. ET to discuss these results.

  • Is Medpace (MEDP) A Great Company to Invest In?
    Insider Monkey

    Is Medpace (MEDP) A Great Company to Invest In?

    Polen Capital, an investment management firm, published its “Polen U.S. SMID Company Growth Composite” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 2.35% was delivered by the fund for the first quarter of 2021, trailing its Russell 2500 Growth benchmark that delivered a 2.49% gain for […]

  • 3 Top Healthcare Stocks to Buy Right Now
    Motley Fool

    3 Top Healthcare Stocks to Buy Right Now

    In the healthcare space, Dexcom (NASDAQ: DXCM), CVS Health (NYSE: CVS), and Medpace Holdings (NASDAQ: MEDP) all have momentum and strong fundamentals on their side. Dexcom, which makes wearable continuous glucose monitoring devices and the software for them, has the rise of the number of diabetes patients worldwide fueling its growth. CVS, known as a drug store company but firmly established as a medical insurer thanks to its purchase of Aetna, is helped by increased foot traffic in its stores as vaccination rates increase in the U.S. Medpace has benefited as companies turn to clinical research organizations to more seamlessly run their drug trials and approval processes for new medical therapies and devices.